non-small cell lung cancer cell line

Olomoucine 是 Cdk2 cyclin A、Cdc2 CyclinB、CDK2 CyclinE、CDK5 p35 和 ERK1 p44 MAP 激酶的 ATP 竞争性抑制剂，IC50 分别为 7、7、7、3 和 25 µM。 Olomoucine 调节细胞周期并表现出抗黑色素肿瘤活性。

EGFR-IN-59 是 EGFR 抑制剂，其IC50值为190 nM，也是一直凋亡 (apoptosis) 诱导剂。EGFR-IN-59 对非小肺癌细胞系 (A549) 和正常肺成纤维细胞 (WI38) 表现出细胞毒性的IC50分别为 8.62 和 52.6 μM。EGFR-IN-59 能够用于研究非小细胞肺癌 (NSCLC)、头颈癌、乳腺癌和结直肠癌等多种癌症。

FJ9 is a FZD7 inhibitor which disrupts protein-protein interaction between Frz7 and the PDZ domain of DVL, and induces apoptosis in melanoma cell line and non-small cell lung cancer cell line.

RKS262 is a specific cyclin CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment.

NSD3-IN-3，一种高效的NSD3抑制剂 (IC50=1.86 μM)，对非小细胞肺癌细胞系H460的生长和增殖具有显著的抑制作用，表现出抗癌活性。

EGFRkinase inhibitor 7 (compound 18i) 作为一种有效的EGFR抑制剂 (IC50=42.3 nM)，在抗癌研究中表现出显著的活性。该化合物在体外实验中显示出高度的细胞毒性以及细胞凋亡 (apoptosis) 诱导能力。此外，EGFRkinase inhibitor 7 对人结肠癌细胞系 HCT116 和人非小细胞肺癌细胞系 A549 亦显示出强效的抑制增殖作用，其中IC50值分别为 4.82 µM 和 1.43 µM。

Agatharesinol acetonide shows anticancer activity towards the A549 non-small-cell lung-cancer cell line (IC50 = 27.1 microM).